CAR-T
Chimeric Antigen Receptor T cells (CAR-T cells) are genetically engineered T lymphocytes designed to specifically recognize and eliminate cancer cells.
By modifying a patient's own T cells to express CARs that target tumor-associated antigens, CAR-T therapy provides a highly personalized and potent form of immunotherapy.
T cell-based immunotherapy began with TILs in the 1980s, leading to CAR-T cell development in the 1990s. FDA approval in 2017 marked a breakthrough in personalized cancer treatment.
To support the advancement of targeted immunotherapy research, Allianz Bio, in collaboration with ACRO, offers a wide range of high-quality reagents and tools designed to accelerate your discovery and development process.
From cutting-edge specialized immune cell lines to transfection reagents, our portfolio is tailored to meet the evolving needs of immunotherapy researchers worldwide.
| Isolation | Culture media & Supplements | Activation | T cell engineering |
|---|---|---|---|
| • Magnetic beads | • Expansion | • Streptavidin | • Nucleic acid removal |
| • Flow cytometry analysis | • Growth Factor | • Magnetic beads | • Gene editing enzyme (AAV titration kit) |
| • Streptavidin | • Cytokines | ||
| • CD Markers |
| CAR evaluation | Cell lines | Kits |
|---|---|---|
| • Car protein target | • Reporter cell line | • Residual kit |
| • MHC molecules | • Overexpression cell line | • ELIspot kit |
| • Anti-CD19 CAR | • Gene knockout cell line | • Biomarker ELISA kit |
| • Car linker antibody | • One-stop cell line solutions | |
| • Bispecific antibody |
Key Features –
- Targeted Action – Engineered to recognize specific tumor antigens (e.g., CD19).
- MHC-Independent – Binds directly to antigens without MHC restriction.
- Enhanced Activation – Includes costimulatory domains (CD28, 4-1BB) for stronger response.
- Potent Cytotoxicity – Kills cancer cells via perforin and granzyme release.
- Long-Term Effect – Some CAR-T cells persist as memory cells to prevent relapse.
More About Principals
ACRO Biosystems provides key reagents for CAR-T therapy, including CAR target proteins (CD19, BCMA), anti-CAR antibodies, MHC molecules, bispecific antibodies, AAV titration kits, ELISpot, and biomarker ELISA kits for evaluation and QC.
Cellecta offers gene editing tools like CRISPR libraries, editing enzymes, and nucleic acid removal kits, enabling efficient T cell engineering and functional screening for CAR-T development.
